Exogenous Expression of Caspase-14 Induces Tumor Suppression in Human Salivary Cancer Cells by Inhibiting Tumor Vascularization
Background: Current therapeutic approaches to salivary gland cancer are often associated with severe disfigurement and loss of glandular function, which are traumatic to the patients. Exploration of novel treatment approaches, such as gene therapy, is needed. Materials and Methods: The human salivar...
Saved in:
Published in | Anticancer research Vol. 29; no. 10; pp. 3811 - 3818 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Attiki
International Institute of Anticancer Research
01.10.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background: Current therapeutic approaches to salivary gland cancer are often associated with severe disfigurement and loss
of glandular function, which are traumatic to the patients. Exploration of novel treatment approaches, such as gene therapy,
is needed. Materials and Methods: The human salivary gland cancer cell line HSG was transiently transfected with full length
human caspase-14 cDNA. Photomicroscopy, BrdU assay, cell counting, MTT assay, and TUNEL assay were applied. To determine the
tumorigenicity, tumor volume, tumor pathology and vascularization were analyzed in vivo. Results: Cell growth and viability
were inhibited significantly by transient caspase-14 expression. Caspase-14 expression resulted in a significant reduction
of tumorigenicity. Importantly, a significant decrease in tumor blood vessel formation was observed. Conclusion: Salivary
gland cancer cells underwent growth inhibition, cell death, and reduced tumorigenicity in vivo when exogenous caspase-14 was
expressed, which could be due, in part, to an inhibitory effect of caspase-14 on tumor vascularization. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this study. |
ISSN: | 0250-7005 1791-7530 |